Supprelin La

(Histrelin)

Phase 3Small molecule

UUniversity of Hertfordshire

Supprelin La is one of 88 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Central Precocious PubertyActive, not recruiting

Prostate CancerActive, not recruiting

Prostate AdenocarcinomaPhase 3

Active, not recruiting

Central Precocious PubertyPhase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Supprelin La

UUniversity of Hertfordshire

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Duragesic

CCephalon

Preclinical

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Triptorelin Pamoate

Ipsen

Preclinical

2 10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT05050084

Q2 2029

Phase 2Recruiting

Prostate Cancer

NCT06378866

Q4 2033

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT04513717

Clinical

Trials by Indication[1]

Prostate Adenocarcinoma2 trials

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruiting·NNRG Oncology·Phase 3·NCT05050084·2,050 enrolled

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruiting·NNRG Oncology·Phase 3·NCT04513717·2,753 enrolled

Prostate Cancer1 trial

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Recruiting·MMayo Clinic·Phase 2·NCT06378866·532 enrolled

Central precocious puberty1 trial

Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

Completed· Endo Pharmaceuticals logo

Endo Pharmaceuticals·Phase 3·NCT00779103·36 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 24, 1991

SUPPRELIN

NDA NDA019836

Oct 12, 2004

VANTAS

NDA NDA021732

May 3, 2007

SUPPRELIN LA

NDA NDA022058

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Histrelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Histrelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Histrelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022058). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Supprelin La. U.S. Food & Drug Administration.
[6]
SEC EDGAR — University of Hertfordshire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Hertfordshire

Patent Landscape[5]

Patent #Expires

8062652Jun 16, 2026

Supprelin La

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2029

Q4 2033

Trials by Indication[1]

Prostate Adenocarcinoma2 trials

Prostate Cancer1 trial

Central precocious puberty1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News